Overview A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED) Status: Completed Trial end date: 2005-11-01 Target enrollment: Participant gender: Summary This study will assess the safety, tolerability, PK, and PD of a once weekly dose of MK0822 in healthy postmenopausal women. Phase: Phase 1 Details Lead Sponsor: Merck Sharp & Dohme Corp.